Verve Therapeutics
Boston
About Verve Therapeutics
Verve Therapeutics develops genetic medicines that target cardiovascular diseases through innovative therapies. The company focuses on creating treatments that address the genetic causes of these conditions, aiming to transform how cardiovascular diseases are managed. As a clinical-stage organization, Verve is engaged in advancing its product candidates through rigorous research and development processes. The company emphasizes its commitment to improving patient outcomes by leveraging genetic insights to develop effective solutions. Verve Therapeutics continues to evolve in the field of genetic medicine, contributing to the future of cardiovascular health.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $419.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2023)
- Ticker: nasdaq:VERV
- Website: vervetx.com
- Phone: +1 617 603 0070
Industries & Categories
Biotechnology, Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/verve-therapeutics-68211 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.